Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Alzheimer's Disease

Free Subscription Articles published in J Neurol Retrieve available abstracts of 75 articles: HTML format

Single Articles

December 2025
1. DUAN X, Wang F, Liu W, Xie Y, et al
   The diagnostic value of plasma Abeta42 and Abeta40 in Alzheimer's disease: current status, challenges, and impacting variables.
   J Neurol. 2025;273:30.
   PubMed     Abstract available
   
   
   
2. GUILLEN N, Esteller D, Sarto J, Perales I, et al
   Plasma p-Tau217 and GFAP predict widespread cognitive decline in Alzheimer's disease.
   J Neurol. 2025;273:28.
   PubMed     Abstract available
   
   
   
3. NA S, Muir K, Lophatananon A, Huang Y, et al
   Physical activity and Alzheimer's disease risk across genetic susceptibility: a prospective UK Biobank study using accelerometer data.
   J Neurol. 2025;273:1.
   PubMed     Abstract available
   
   
   November 2025
4. BUONOCORE J, Fratto E, Arcuri F, Vescio B, et al
   Plasma NfL and GFAP in the preclinical stages of neurodegenerative diseases: insights from the UK Biobank.
   J Neurol. 2025;272:755.
   PubMed     Abstract available
   
   
   
5. NOLI B, Muqaku B, Gouda M, Manai AL, et al
   VGF AQEE- and GGEE-peptides differentiate between dementia types.
   J Neurol. 2025;272:745.
   PubMed     Abstract available
   
   
   October 2025
6. GUO X, Yue R, Cui Z, Wang S, et al
   Advances of therapeutic strategies for Alzheimer's disease.
   J Neurol. 2025;272:705.
   PubMed     Abstract available
   
   
   
7. HUANG XT, Huang LY, Tan CC, Wei JM, et al
   The role of APOE epsilon4 in modulating the relationship between non-genetic risk factors and dementia: a system review and meta-analysis.
   J Neurol. 2025;272:690.
   PubMed     Abstract available
   
   
   
8. ELKANA O, Beheshti I
   Brain age as an accurate biomarker of preclinical cognitive decline: evidence from a 12-year longitudinal study.
   J Neurol. 2025;272:672.
   PubMed     Abstract available
   
   
   
9. WADOP YN, Bernal R, Njamnshi WY, Satizabal CL, et al
   Altered gut microbiota mediates the association between APOE genotype and amyloid-beta accumulation in middle-aged adults.
   J Neurol. 2025;272:670.
   PubMed     Abstract available
   
   
   
10. MAZZEO S, Boveri S, Bortolin E, Bruschi G, et al
    Data-driven subtypes of subjective cognitive decline: neuropsychological profiles, Alzheimer's disease biomarkers, and clinical trajectories.
    J Neurol. 2025;272:669.
    PubMed     Abstract available
    
    
    September 2025
11. SCHMIDT CC, Bardakan MM, Jaeger E, Richter N, et al
    Apraxic deficits predict general cognitive impairment in patients with biomarker-verified Alzheimer's pathology.
    J Neurol. 2025;272:654.
    PubMed     Abstract available
    
    
    
12. ALMEIDA FC, Santos A, Jesus T, Gauthreaux K, et al
    Amygdala-predominant Lewy bodies associate with cognitive decline and amygdala atrophy in Alzheimer's disease neuropathological change.
    J Neurol. 2025;272:629.
    PubMed     Abstract available
    
    
    August 2025
13. ZHANG Q, Lu J, Wang L, Jiao F, et al
    Evaluating (18)F-Florzolotau tau PET for Alzheimer's disease diagnosis with (18)F-Flortaucipir as reference.
    J Neurol. 2025;272:597.
    PubMed     Abstract available
    
    
    
14. MAZZEO S, Crucitti C, Lassi M, Ingannato A, et al
    The HTT gene influences plasma neurofilament light chain and brain metabolism in prodromal Alzheimer's disease.
    J Neurol. 2025;272:588.
    PubMed     Abstract available
    
    
    
15. DENG Z, Huang Z, Ge H, Wang H, et al
    Diagnostic performance of choroid plexus and cerebrospinal fluid space volumes in idiopathic normal pressure hydrocephalus.
    J Neurol. 2025;272:550.
    PubMed     Abstract available
    
    
    June 2025
16. LACZO M, Svacova Z, Lerch O, Martinkovic L, et al
    Spatial navigation deficits in early Alzheimer's disease: the role of biomarkers and APOE genotype.
    J Neurol. 2025;272:438.
    PubMed     Abstract available
    
    
    May 2025
17. ROSENBLOOM M, Schnee A, Nimma S, Lutz H, et al
    Monoclonal antibody administration in an academic institution and private neurological practice: a tale of two clinics.
    J Neurol. 2025;272:394.
    PubMed     Abstract available
    
    
    April 2025
18. MITTLER B, Cambi X, Biskach M, Reisman J, et al
    Patient journey and decision processes for anti-amyloid therapy in Alzheimer's disease.
    J Neurol. 2025;272:341.
    PubMed     Abstract available
    
    
    March 2025
19. KORIATH CAM, Rauchmann B, Schoeberl F, Zwergal A, et al
    Vestibular dysfunction: a hidden risk factor for Alzheimer's disease.
    J Neurol. 2025;272:285.
    PubMed     Abstract available
    
    
    
20. ZHANG X, Irish M, Piguet O, Ahmed RM, et al
    Behavioural and cognitive profiles in frontotemporal dementia and Alzheimer's disease: a longitudinal study.
    J Neurol. 2025;272:279.
    PubMed     Abstract available
    
    
    
21. JIANG Y, Jin Z, Wang H, He X, et al
    A dose-response meta-analysis of physical activity and the risk of alzheimer's disease in prospective studies.
    J Neurol. 2025;272:256.
    PubMed     Abstract available
    
    
    
22. ANTONIONI A, Raho EM, Di Lorenzo F, Manzoli L, et al
    Blood phosphorylated Tau217 distinguishes amyloid-positive from amyloid-negative subjects in the Alzheimer's disease continuum. A systematic review and meta-analysis.
    J Neurol. 2025;272:252.
    PubMed     Abstract available
    
    
    
23. BUCHHOLZ E, Machule ML, Buthut M, Stefanovski L, et al
    Overlapping presence of beta-amyloid, tau, p-tau, and alpha-synuclein in skin nerve fibers in Alzheimer's disease.
    J Neurol. 2025;272:247.
    PubMed     Abstract available
    
    
    January 2025
24. ZAVARELLA M, Cecchetti G, Rugarli G, Ghirelli A, et al
    Favorable long-term cognitive outcomes following recurrent ARIA linked to amyloid-lowering therapies: two cases.
    J Neurol. 2025;272:168.
    PubMed     Abstract available
    
    
    
25. SARTO J, Esteller-Gauxax D, Guillen N, Falgas N, et al
    Accuracy and clinical applicability of plasma tau 181 and 217 for Alzheimer's disease diagnosis in a memory clinic cohort.
    J Neurol. 2025;272:160.
    PubMed     Abstract available
    
    
    
26. PRASAD P, Gbadegesin O, Edwards M
    Correction: Evolving management of Alzheimer's disease.
    J Neurol. 2025;272:156.
    PubMed    
    
    
    
27. ZHAO C, Li T, Hao S, Zhao L, et al
    Dysregulation of the molecular clock by blood-borne factors in Alzheimer's disease patients.
    J Neurol. 2025;272:121.
    PubMed     Abstract available
    
    
    December 2024
28. ZILIOLI A, Rosenberg A, Mohanty R, Matton A, et al
    Brain MRI volumetry and atrophy rating scales as predictors of amyloid status and eligibility for anti-amyloid treatment in a real-world memory clinic setting.
    J Neurol. 2024;272:84.
    PubMed     Abstract available
    
    
    
29. RAPOSO PEREIRA F, Chaumon M, Dubois B, Bakardjian H, et al
    Recognition memory decline is associated with the progression to prodromal Alzheimer's disease in asymptomatic at-risk individuals.
    J Neurol. 2024;272:70.
    PubMed     Abstract available
    
    
    
30. ERATNE D, Li QX, Lewis C, Dang C, et al
    Strong diagnostic performance of plasma ptau217 for CSF biomarker-defined young-onset Alzheimer disease in a diagnostically heterogeneous clinical cohort.
    J Neurol. 2024;272:25.
    PubMed     Abstract available
    
    
    
31. YUAN Y, Zhao G, Zhao Y
    Dysregulation of energy metabolism in Alzheimer's disease.
    J Neurol. 2024;272:2.
    PubMed     Abstract available
    
    
    
32. MUQAKU B, Anderl-Straub S, Werner L, Nagl M, et al
    Contactin proteins in cerebrospinal fluid show different alterations in dementias.
    J Neurol. 2024;271:7516-7524.
    PubMed     Abstract available
    
    
    November 2024
33. PRASAD P, Gbadegesin O, Edwards M
    Evolving management of Alzheimer's disease.
    J Neurol. 2024 Nov 9. doi: 10.1007/s00415-024-12720.
    PubMed    
    
    
    September 2024
34. MITOLO M, Lombardi G, Manca R, Nacmias B, et al
    Association between blood-based protein biomarkers and brain MRI in the Alzheimer's disease continuum: a systematic review.
    J Neurol. 2024 Sep 12. doi: 10.1007/s00415-024-12674.
    PubMed     Abstract available
    
    
    
35. TABUAS-PEREIRA M, Bernardes C, Duraes J, Lima M, et al
    Exploring first-degree family history in a cohort of Portuguese Alzheimer's disease patients: population evidence for X-chromosome linked and recessive inheritance of risk factors.
    J Neurol. 2024 Sep 5. doi: 10.1007/s00415-024-12673.
    PubMed     Abstract available
    
    
    August 2024
36. CECCHETTI G, Agosta F, Rugarli G, Spinelli EG, et al
    Diagnostic accuracy of automated Lumipulse plasma pTau-217 in Alzheimer's disease: a real-world study.
    J Neurol. 2024 Aug 22. doi: 10.1007/s00415-024-12631.
    PubMed     Abstract available
    
    
    
37. SHAW SR, Horne KS, Piguet O, Ahmed RM, et al
    Profiles of motivational impairment and their relationship to functional decline in frontotemporal dementia.
    J Neurol. 2024;271:4963-4971.
    PubMed     Abstract available
    
    
    June 2024
38. FOXE D, Irish M, Carrick J, Cheung SC, et al
    Correction to: Visuospatial working memory in behavioural variant frontotemporal dementia: a comparative analysis with Alzheimer's disease using the box task.
    J Neurol. 2024 Jun 21. doi: 10.1007/s00415-024-12483.
    PubMed    
    
    
    
39. LI KY, Chien CF, Huang LC, Lim K, et al
    Exploring the impact of 40 Hz multi-luminaire light exposure in Alzheimer's dementia: insights from a convenient sampling, non-randomized case-control study.
    J Neurol. 2024 Jun 17. doi: 10.1007/s00415-024-12486.
    PubMed     Abstract available
    
    
    May 2024
40. FOXE D, Irish M, Carrick J, Cheung SC, et al
    Visuospatial working memory in behavioural variant frontotemporal dementia: a comparative analysis with Alzheimer's disease using the box task.
    J Neurol. 2024 May 7. doi: 10.1007/s00415-024-12406.
    PubMed     Abstract available
    
    
    
41. CANU E, Rugarli G, Coraglia F, Basaia S, et al
    Real-word application of the AT(N) classification and disease-modifying treatment eligibility in a hospital-based cohort.
    J Neurol. 2024;271:2716-2729.
    PubMed     Abstract available
    
    
    April 2024
42. WANG S, Zheng X, Huang J, Liu J, et al
    Sleep characteristics and risk of Alzheimer's disease: a systematic review and meta-analysis of longitudinal studies.
    J Neurol. 2024 Apr 24. doi: 10.1007/s00415-024-12380.
    PubMed     Abstract available
    
    
    
43. ZAMBONI G, Maramotti R, Salemme S, Tondelli M, et al
    Age-specific prevalence of the different clinical presentations of AD and FTD in young-onset dementia.
    J Neurol. 2024 Apr 21. doi: 10.1007/s00415-024-12364.
    PubMed     Abstract available
    
    
    
44. GUILOFF AE, Rudge P
    Amyloid antibody therapy for early-stage Alzheimer's disease: a critical review of three recent trials.
    J Neurol. 2024 Apr 13. doi: 10.1007/s00415-024-12361.
    PubMed    
    
    
    
45. LAVROVA A, Pham NTT, Vernon CJ, Carlos AF, et al
    A multimodal clinical diagnostic approach using MRI and (18)F-FDG-PET for antemortem diagnosis of TDP-43 in cases with low-intermediate Alzheimer's disease neuropathologic changes and primary age-related tauopathy.
    J Neurol. 2024 Apr 5. doi: 10.1007/s00415-024-12312.
    PubMed     Abstract available
    
    
    
46. MENDES AJ, Ribaldi F, Lathuiliere A, Ashton NJ, et al
    Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort.
    J Neurol. 2024;271:2053-2066.
    PubMed     Abstract available
    
    
    
47. O'CONNOR A, Lyons S, Finnegan M, Walsh J, et al
    Expanding the phenotype of psychiatric-onset prodromal dementia with Lewy bodies.
    J Neurol. 2024;271:2125-2128.
    PubMed    
    
    
    
48. SARTO J, Esteller-Gauxax D, Tort-Merino A, Guillen N, et al
    Impact of demographics and comorbid conditions on plasma biomarkers concentrations and their diagnostic accuracy in a memory clinic cohort.
    J Neurol. 2024;271:1973-1984.
    PubMed     Abstract available
    
    
    March 2024
49. LANGERSCHEIDT F, Wied T, Al Kabbani MA, van Eimeren T, et al
    Genetic forms of tauopathies: inherited causes and implications of Alzheimer's disease-like TAU pathology in primary and secondary tauopathies.
    J Neurol. 2024 Mar 30. doi: 10.1007/s00415-024-12314.
    PubMed     Abstract available
    
    
    
50. SINGH NA, Graff-Radford J, Machulda MM, Carlos AF, et al
    Atypical Alzheimer's disease: new insights into an overlapping spectrum between the language and visual variants.
    J Neurol. 2024 Mar 29. doi: 10.1007/s00415-024-12297.
    PubMed     Abstract available
    
    
    
51. PENG M, Yuan S, Lu D, Ling Y, et al
    Dietary inflammatory index, genetic susceptibility and risk of incident dementia: a prospective cohort study from UK biobank.
    J Neurol. 2024;271:1286-1296.
    PubMed     Abstract available
    
    
    February 2024
52. SUBOTIC A, Gee M, Nelles K, Ba F, et al
    Gray matter loss relates to dual task gait in Lewy body disorders and aging.
    J Neurol. 2024;271:962-975.
    PubMed     Abstract available
    
    
    January 2024
53. HUANG M, Landin-Romero R, Matis S, Dalton MA, et al
    Longitudinal volumetric changes in amygdala subregions in frontotemporal dementia.
    J Neurol. 2024 Jan 24. doi: 10.1007/s00415-023-12172.
    PubMed     Abstract available
    
    
    
54. GENG C, Meng K, Tang Y
    Identifying the mediating role of inflammation on the relationship between socioeconomic status and Alzheimer's disease: a Mendelian randomization analysis and mediation analysis.
    J Neurol. 2024 Jan 22. doi: 10.1007/s00415-023-12176.
    PubMed     Abstract available
    
    
    
55. HENNEY AE, Gillespie CS, Alam U, Hydes TJ, et al
    High intake of ultra-processed food is associated with dementia in adults: a systematic review and meta-analysis of observational studies.
    J Neurol. 2024;271:198-210.
    PubMed     Abstract available
    
    
    December 2023
56. MASSA F, Martinuzzo C, Gomez de San Jose N, Pelagotti V, et al
    Cerebrospinal fluid NPTX2 changes and relationship with regional brain metabolism metrics across mild cognitive impairment due to Alzheimer's disease.
    J Neurol. 2023 Dec 29. doi: 10.1007/s00415-023-12154.
    PubMed     Abstract available
    
    
    
57. RONAT L, Hanganu A, Chylinski D, Van Egroo M, et al
    Prediction of cognitive decline in healthy aging based on neuropsychiatric symptoms and PET-biomarkers of Alzheimer's disease.
    J Neurol. 2023 Dec 19. doi: 10.1007/s00415-023-12131.
    PubMed     Abstract available
    
    
    November 2023
58. ST-GEORGES MA, Wang L, Chapleau M, Migliaccio R, et al
    Social cognition and behavioral changes in patients with posterior cortical atrophy.
    J Neurol. 2023 Nov 30. doi: 10.1007/s00415-023-12089.
    PubMed     Abstract available
    
    
    
59. PEREZ-MILLAN A, Borrego-Ecija S, Falgas N, Junca-Parella J, et al
    Cortical thickness modeling and variability in Alzheimer's disease and frontotemporal dementia.
    J Neurol. 2023 Nov 27. doi: 10.1007/s00415-023-12087.
    PubMed     Abstract available
    
    
    
60. VRILLON A, Ashton NJ, Karikari TK, Gotze K, et al
    Comparison of CSF and plasma NfL and pNfH for Alzheimer's disease diagnosis: a memory clinic study.
    J Neurol. 2023 Nov 11. doi: 10.1007/s00415-023-12066.
    PubMed     Abstract available
    
    
    September 2023
61. STAM D, Rosseel S, De Winter FL, Van den Bossche MJA, et al
    Facial expression recognition deficits in frontotemporal dementia and Alzheimer's disease: a meta-analytic investigation of effects of phenotypic variant, task modality, geographical region and symptomatic specificity.
    J Neurol. 2023 Sep 6. doi: 10.1007/s00415-023-11927.
    PubMed     Abstract available
    
    
    
62. CHAN E, Bonifacio GB, Harrison C, Banerjee G, et al
    Domain-specific neuropsychological investigation of CAA with and without intracerebral haemorrhage.
    J Neurol. 2023 Sep 6. doi: 10.1007/s00415-023-11977.
    PubMed     Abstract available
    
    
    
63. DAMSGAARD L, Janbek J, Laursen TM, Waldemar G, et al
    Healthcare utilization prior to a diagnosis of young-onset Alzheimer's disease: a nationwide nested case-control study.
    J Neurol. 2023 Sep 5. doi: 10.1007/s00415-023-11974.
    PubMed     Abstract available
    
    
    July 2023
64. PENA-BAUTISTA C, Alvarez-Sanchez L, Ferrer-Cairols I, Garcia-Valles L, et al
    Assessment of COVID-19 lockdown effect on early Alzheimer Disease progression.
    J Neurol. 2023 Jul 28. doi: 10.1007/s00415-023-11899.
    PubMed     Abstract available
    
    
    
65. MIZUTANI Y, Ohdake R, Tatebe H, Higashi A, et al
    Associations of Alzheimer's-related plasma biomarkers with cognitive decline in Parkinson's disease.
    J Neurol. 2023 Jul 22. doi: 10.1007/s00415-023-11875.
    PubMed     Abstract available
    
    
    
66. SAW AM, Hrastelj J, Robertson NP
    Path from discovery to recovery: therapeutic and diagnostic advances in Alzheimer's dementia.
    J Neurol. 2023 Jul 3. doi: 10.1007/s00415-023-11840.
    PubMed    
    
    
    June 2023
67. KUCIKOVA L, Zeng J, Munoz-Neira C, Muniz-Terrera G, et al
    Genetic risk factors of Alzheimer's Disease disrupt resting-state functional connectivity in cognitively intact young individuals.
    J Neurol. 2023 Jun 26. doi: 10.1007/s00415-023-11809.
    PubMed     Abstract available
    
    
    April 2023
68. LING Y, Yuan S, Huang X, Tan S, et al
    The association of night shift work with the risk of all-cause dementia and Alzheimer's disease: a longitudinal study of 245,570 UK Biobank participants.
    J Neurol. 2023 Apr 6. doi: 10.1007/s00415-023-11672.
    PubMed     Abstract available
    
    
    
69. FERRUCCI R, Cuffaro L, Capozza A, Rosci C, et al
    Brain positron emission tomography (PET) and cognitive abnormalities one year after COVID-19.
    J Neurol. 2023;270:1823-1834.
    PubMed     Abstract available
    
    
    
70. TAYLOR NL, Shine JM
    A whole new world: embracing the systems-level to understand the indirect impact of pathology in neurodegenerative disorders.
    J Neurol. 2023;270:1969-1975.
    PubMed     Abstract available
    
    
    
71. CONSTANTINIDES VC, Tentolouris-Piperas V, Paraskevas GP, Pyrgelis ES, et al
    Hippocampal subfield volumetry in corticobasal syndrome of diverse underlying pathologies.
    J Neurol. 2023;270:2059-2068.
    PubMed     Abstract available
    
    
    March 2023
72. SEMENKOVA A, Piguet O, Johnen A, Schroeter ML, et al
    The Behavioural Dysfunction Questionnaire discriminates behavioural variant frontotemporal dementia from Alzheimer's disease dementia and major depressive disorder.
    J Neurol. 2023 Mar 23. doi: 10.1007/s00415-023-11666.
    PubMed     Abstract available
    
    
    
73. FILIPPI M, Cecchetti G, Cagnin A, Marra C, et al
    Redefinition of dementia care in Italy in the era of amyloid-lowering agents for the treatment of Alzheimer's disease: an expert opinion and practical guideline.
    J Neurol. 2023 Mar 9. doi: 10.1007/s00415-023-11642.
    PubMed     Abstract available
    
    
    February 2023
74. JISKOOT LC, Russell LL, Greaves CV, van Schaik E, et al
    Addition of the FTD Module to the Neuropsychiatric Inventory improves classification of frontotemporal dementia spectrum disorders.
    J Neurol. 2023 Feb 22. doi: 10.1007/s00415-023-11596.
    PubMed     Abstract available
    
    
    January 2023
75. CRETIN B, Philippi N, Bousiges O, Blanc F, et al
    Transient epileptic amnesia: a retrospective cohort study of 127 cases, including CSF amyloid and tau features.
    J Neurol. 2023 Jan 30. doi: 10.1007/s00415-023-11576.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Alzheimer's Disease is free of charge.